One dose, not two: what WHO's advisers have just said about the HPV jab
What happened
The World Health Organization's expert vaccine panel has changed its advice on the HPV jab. The panel is called SAGE, short for the Strategic Advisory Group of Experts on Immunization. It met from 5 to 8 October 2026 and set out its conclusions at a press conference in Geneva on Tuesday 13 October 2026. The headline is this: SAGE now says a single dose of HPV vaccine for girls aged 9 to 14 is the most efficient way to reach the world's target for preventing cervical cancer. Until now, a single dose had been treated as an acceptable alternative to two. SAGE has moved it to the front. There is a second, more surprising part. SAGE said countries may also consider offering routine vaccination to girls aged 4 to 8, if doing that is likely to get more children vaccinated. Professor Anthony Scott, who chairs SAGE, said: 'Countries may also consider routine vaccination (for) girls aged 4 to 8 years.' SAGE also set out an order for widening the programme using single doses: catch-up for women up to 25, then women up to 30, then routine vaccination for boys aged 9 to 14, then catch-up for males up to 20. One group is specifically excluded from the single-dose advice. People who are immunocompromised, including those with well-controlled HIV, should still have two doses. People who are severely immunocompromised should have three. The reason for the change is coverage. Professor Scott said: 'However, the global HPV vaccine coverage, at 33%, is far short of the global target we're looking for, which is 90%.'
Why this matters
HPV stands for human papillomavirus. It is a very common virus, passed on by skin-to-skin contact. Most people clear it without ever knowing they had it. In a small number of people it lingers, and over many years it can cause cell changes that turn into cancer. Cervical cancer is the one most people know about, and it is the fifth most commonly diagnosed cancer in women worldwide. In 2024 there were around 604,000 new cases and around 280,000 deaths. In 26 countries, it is the leading cause of cancer death in women. The vaccine works. That is not the argument. The argument has been about how many doses you need, and the answer matters enormously for practical reasons. Two doses means finding the same child twice, often months apart. In many countries that second visit is where the programme falls down. Children move, families move, clinics run short of staff, funding is squeezed. Kate O'Brien, who directs WHO's immunisation department, said funding shortfalls and staffing pressures make evidence-based vaccine policies 'more critical than ever'. If one dose does the job, every dose that was going to be a second dose can instead be a first dose for a child who has had none. That is how you move coverage from 33% towards 90% without doubling the budget. About 165 countries have introduced the HPV vaccine, and more than 95 million girls had been vaccinated by the end of 2025. There are eight licensed HPV vaccines.
What the evidence actually says
It is worth separating what has changed from what has not. What has changed is the ranking. SAGE has looked again at the evidence and concluded that a one-dose schedule for girls aged 9 to 14 is the most efficient strategy. 'Efficient' is doing real work in that sentence. It means best protection for the effort, cost and doses available, across a whole population. It is a public health judgement about programmes, not a promise that one dose is identical to two in every individual. What has not changed is the basic science. The vaccine protects against the HPV types that cause most cervical cancers, and protection appears to last. Annelies Wilder-Smith, SAGE's executive secretary, framed the update plainly: as evidence and public health needs change, 'our recommendations must evolve accordingly.' The advice on girls aged 4 to 8 is the part to read most carefully. SAGE did not say younger is better. It said countries *may consider* it, and only where it is likely to increase uptake and coverage. In some countries, vaccines are easier to deliver to younger children because they are already in contact with health services. That is an operational argument, not a claim that a four-year-old needs protecting now. The carve-out for immunocompromised people is also important, and it cuts the other way. For those groups the advice is more doses, not fewer: two for people who are immunocompromised, including well-controlled HIV, and three for those who are severely immunocompromised. Finally, a note on what this is. SAGE advises WHO. Individual countries, including the UK, set their own schedules through their own expert committees. A SAGE recommendation does not automatically change what your child is offered at school.
Practical advice
If you are a parent in the UK, the most useful thing you can do is not change anything based on this news. The NHS already offers the HPV vaccine to young people, and England moved to a single-dose schedule for most young people some time ago. The decision about what the NHS offers is made by the UK's own expert committee, not by SAGE. So if your child has an HPV vaccination appointment, keep it. If you have been sent a consent form, fill it in. What this news does usefully do is answer a question lots of parents ask: is one dose really enough? The world's leading vaccine advisory panel has now looked at the evidence and said that for girls aged 9 to 14, one dose is the most efficient way to protect a population. That is a reassuring answer if you were worried that a single-dose schedule was a cost-cutting shortcut. If your child missed the jab at school, it is usually not too late. Speak to your GP surgery or your school's immunisation team and ask about catch-up. SAGE has put catch-up for young women near the top of its priority list for a reason. If you or your child has a condition that affects the immune system, or you are on medicine that suppresses it, this is the one case where you should actively raise it. The advice for those groups is more doses, not fewer. Your specialist or GP can advise. And a reminder that applies whatever your vaccination status: the vaccine does not replace cervical screening. Screening picks up changes the vaccine was never designed to prevent. If you get an invitation, take it.
What to know
WHO's expert vaccine panel SAGE met from 5 to 8 October 2026 and announced on 13 October that a single HPV dose for girls aged 9 to 14 is now considered the most efficient way to prevent cervical cancer. Countries may consider vaccinating girls aged 4 to 8 where that would raise coverage. People who are immunocompromised should still have two or three doses. The driver is coverage, not a new discovery. Global coverage sits at 33% against a 90% target, and one dose frees up supply and staff time. For UK families, nothing needs to change today. Keep appointments, ask about catch-up if one was missed, and keep going to cervical screening when invited. Sources: CIDRAP, University of Minnesota, 'One HPV vaccine dose often sufficient, say WHO advisers', October 2026, https://www.cidrap.umn.edu/public-health/one-hpv-vaccine-dose-often-sufficient-say-who-advisers; Medical Xpress, 'WHO experts recommend HPV shot for girls aged 4-8', 13 October 2026, https://medicalxpress.com/news/2026-10-experts-hpv-shot-girls-aged.html. This article is for general information and does not replace advice from a doctor, pharmacist, nurse or other qualified healthcare professional. Decisions about vaccination for you or your child should be made with your own healthcare team.
Related articles
47% stayed off, 14% called anyone: what 68,000 surveys say about how we handle flu
On 15 October 2026, the UK Health Security Agency (UKHSA) published new findings about what people actually do when they come down with flu-like symptoms. The…
3.5 million deaths a year, and no level of it is safe
On 15 October 2026, the World Health Organization (WHO) published an update calling on countries to speed up action against lead poisoning. It came just before…
Over 12,000 fake pens, and packaging for 30,000 more
On 14 October 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police raided an industrial unit in Birmingham. They announc…